摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methyl 2-chloro-5-[3-(2-methoxy-4-(5-phenylpentyloxy)phenyl)propanoylamino]benzoate | 475596-72-6

中文名称
——
中文别名
——
英文名称
methyl 2-chloro-5-[3-(2-methoxy-4-(5-phenylpentyloxy)phenyl)propanoylamino]benzoate
英文别名
methyl 2-chloro-5-[3-[2-methoxy-4-(5-phenylpentoxy)phenyl]propanoylamino]benzoate
methyl 2-chloro-5-[3-(2-methoxy-4-(5-phenylpentyloxy)phenyl)propanoylamino]benzoate化学式
CAS
475596-72-6
化学式
C29H32ClNO5
mdl
——
分子量
510.03
InChiKey
AVAXYLZIUYEZCZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.6
  • 重原子数:
    36
  • 可旋转键数:
    14
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.31
  • 拓扑面积:
    73.9
  • 氢给体数:
    1
  • 氢受体数:
    5

反应信息

点击查看最新优质反应信息

文献信息

  • Carboxylic acid derivatives and drugs containing the same as the active ingredient
    申请人:——
    公开号:US20040224941A1
    公开(公告)日:2004-11-11
    Compounds represented by formula (I), prodrugs thereof and salts thereof, and pharmaceutical compositions comprising the same as an active ingredient (wherein each symbol has the meaning as defined in the specification.). 1 Because of having an EDG-1 agonism, the compounds represented by formula (I) are useful in preventing and/or treating peripheral arterial disease such as arteriosclerosis obliterans, thromboangiitis obliterans, Buerger's disease or diabetic neuropathy, sepsis, angiitis, nephritis, pneumonia, stroke, myocardial infarction, edematous state, atherosclerosis, varicosity such as hemorrhoid, anal fissure or fistula ani, dissecting aneurysm of the aorta, angina, DIC, pleuritis, congestive heart failure, multiple organ failure, bedsore, burn, chronic ulcerative colitis, Crohn's disease, heart transplantation, renal transplantation, dermal graft, liver transplantation, osteoporosis, pulmonary fibrosis, interstitial pneumonia, chronic hepatitis, liver cirrhosis, chronic renal failure, or glomerular sclerosis.
    化学式(I)所代表的化合物、其前药和盐,以及包含其作为活性成分的药物组合物(其中每个符号的含义如规范中所定义)。由于具有EDG-1激动作用,化学式(I)所代表的化合物在预防和/或治疗外周动脉疾病(如动脉硬化闭塞症、血栓闭塞性血管炎、布氏病或糖尿病神经病变)、败血症、血管炎、肾炎、肺炎、中风、心肌梗死、水肿状态、动脉硬化、静脉曲张(如痔疮、肛裂或肛门瘘)、主动脉夹层动脉瘤、心绞痛、DIC、胸膜炎、充血性心力衰竭、多器官衰竭、褥疮、烧伤、慢性溃疡性结肠炎、克罗恩病、心脏移植、肾脏移植、皮肤移植、肝脏移植、骨质疏松症、肺纤维化、间质性肺炎、慢性肝炎、肝硬化、慢性肾衰竭或肾小球硬化方面非常有用。
  • Carboxylic acid derivatives and pharmaceutical compositions comprising the same as an active ingredient
    申请人:Seko Takuya
    公开号:US20070088027A1
    公开(公告)日:2007-04-19
    Compounds represented by formula (I), prodrugs thereof and salts thereof, and pharmaceutical compositions comprising the same as an active ingredient (wherein each symbol has the meaning as defined in the specification.). Because of having an EDG-1 agonism, the compounds represented by formula (I) are useful in preventing and/or treating peripheral arterial disease such as arteriosclerosis obliterans, thromboangiitis obliterans, Buerger's disease or diabetic neuropathy, sepsis, angiitis, nephritis, pneumonia, stroke, myocardial infarction, edematous state, atherosclerosis, varicosity such as hemorrhoid, anal fissure or fistula ani, dissecting aneurysm of the aorta, angina, DIC, pleuritis, congestive heart failure, multiple organ failure, bedsore, burn, chronic ulcerative colitis, Crohn's disease, heart transplantation, renal transplantation, dermal graft, liver transplantation, osteoporosis, pulmonary fibrosis, interstitial pneumonia, chronic hepatitis, liver cirrhosis, chronic renal failure, or glomerular sclerosis.
    化学式(I)所代表的化合物,其前体和盐,以及作为活性成分的药物组合物(其中每个符号的含义均如规范中定义)。 由于具有EDG-1激动作用,化学式(I)所代表的化合物在预防和/或治疗外周动脉疾病,如动脉硬化闭塞症、栓塞性血管炎、布尔格病或糖尿病神经病变、败血症、血管炎、肾炎、肺炎、中风、心肌梗死、水肿状态、动脉粥样硬化、痔核、肛裂或肛门瘘、主动脉夹层、心绞痛、DIC、胸膜炎、充血性心力衰竭、多器官衰竭、褥疮、烧伤、慢性溃疡性结肠炎、克罗恩病、心脏移植、肾移植、皮肤移植、肝移植、骨质疏松症、肺纤维化、间质性肺炎、慢性肝炎、肝硬化、慢性肾功能衰竭或肾小球硬化方面具有用途。
  • US7179817B2
    申请人:——
    公开号:US7179817B2
    公开(公告)日:2007-02-20
  • CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
    申请人:ONO PHARMACEUTICAL CO., LTD.
    公开号:EP1391199B1
    公开(公告)日:2008-12-10
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐